Next Article in Journal
Sulfated Metabolites of Flavonolignans and 2,3-Dehydroflavonolignans: Preparation and Properties
Next Article in Special Issue
Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late
Previous Article in Journal
Quantum Modeling: A Bridge between the Pumping and Signaling Functions of Na/K-ATPase
Previous Article in Special Issue
Vitamin D and Endometrium: A Systematic Review of a Neglected Area of Research
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(8), 2348;

Modeling Endometrial Cancer: Past, Present, and Future

Department of Oncology, Gynecological Oncology, KU Leuven, 3000 Leuven, Belgium
Pathological Oncology Group, Biomedical Research Institute of Lleida (IRBLLEIDA), University Hospital Arnau de Vilanova, 25198 Lleida, Spain
Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, Spain
Centre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek-Netherlands Cancer Institute (Avl-NKI) and University Medical Centra (UMC), 1066 CX Amsterdam, The Netherlands
Author to whom correspondence should be addressed.
Received: 30 June 2018 / Revised: 31 July 2018 / Accepted: 3 August 2018 / Published: 9 August 2018
(This article belongs to the Special Issue Molecular Research of Endometrial Pathophysiology)
Full-Text   |   PDF [538 KB, uploaded 10 August 2018]   |  


Endometrial cancer is the most common type of cancer of the female reproductive tract. Although prognosis is generally good for patients with low-grade and early-stage diseases, the outcomes for high-grade and metastatic/recurrent cases remain poor, since traditional chemotherapy regimens based on platinum and taxanes have limited effects. No targeted agents have been approved so far, although several new drugs have been tested without striking results in clinical trials. Over the last decades, many efforts have been made towards the establishment and development of preclinical models, aiming at recapitulating the structural and molecular determinants of the disease. Here, we present an overview of the most commonly used in vitro and in vivo models and discuss their peculiar features, describing their main applications and the value in the advancement of both fundamental and translational endometrial cancer research. View Full-Text
Keywords: endometrial cancer; preclinical models; translational research endometrial cancer; preclinical models; translational research

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Van Nyen, T.; Moiola, C.P.; Colas, E.; Annibali, D.; Amant, F. Modeling Endometrial Cancer: Past, Present, and Future. Int. J. Mol. Sci. 2018, 19, 2348.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top